Holen Sie sich die Stockscreener-App
25.24
4.25%
-1.1274
Schlusskurs vom Vortag:
$26.37
Offen:
$25.86
24-Stunden-Volumen:
119.34K
Relative Volume:
0.22
Marktkapitalisierung:
$1.40B
Einnahmen:
$2.50M
Nettoeinkommen (Verlust:
$-131.12M
KGV:
-8.8785
EPS:
-2.8431
Netto-Cashflow:
$-112.73M
1W Leistung:
-5.50%
1M Leistung:
-11.87%
6M Leistung:
-43.97%
1J Leistung:
+54.52%
1-Tages-Spanne:
$25.19
$26.55
1-Wochen-Bereich:
$25.19
$26.96
52-Wochen-Spanne:
$15.70
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
25.23 | 1.46B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
522.72 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.34 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.96 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.64 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.05 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-10 | Eingeleitet | Mizuho | Outperform |
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Maze therapeutics president, R&D & CMO, sells $254,501 in shares By Investing.com - Investing.com Canada
Maze therapeutics president, R&D & CMO, sells $254,501 in shares - Investing.com India
Maze Therapeutics (MAZE) R&D chief exits direct stake - Stock Titan
Maze Therapeutics CEO Coloma Jason V Offloads 22,638 Shares at $25.77 to $27.12 Each - Kalkine Media
Don't Ignore The Insider Selling In Maze Therapeutics - simplywall.st
Courtney Phillips Executes 11,000 Zero-Cost Options in Maze Therapeutics (NASDAQ: MAZE) on September 1, 2026 - Kalkine Media
Maze Therapeutics CSBO Atul Dandekar Sells 6,434 Shares to Cover RSU Tax Withholding - Kalkine Media
Maze Therapeutics (NASDAQ: MAZE) officer lines up new stock sale after recent 10b5-1 trades - Stock Titan
Maze Therapeutics Chief Executive Officer Sold Shares Worth Over $593K - TradingView
Maze Therapeutics (MAZE) legal chief sells stock for taxes - Stock Titan
Insider at Maze Therapeutics (MAZE) sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) CEO sells shares to cover taxes - Stock Titan
Maze Therapeutics (MAZE) R&D chief sells shares to cover RSU taxes - Stock Titan
Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - Kalkine
Maze Therapeutics Officer Courtney Phillips Reports RSU Vesting and Stock Settlement - Kalkine Media
Maze Therapeutics CEO Jason V Coloma Reports RSU Vesting and Trust Share Sales in Form 4 Filing - Kalkine Media
RSU vesting gives Maze Therapeutics (MAZE) exec 12,500 shares - Stock Titan
Maze Therapeutics (MAZE) CEO gets 50K shares, trims stake via trust sales - Stock Titan
Rule-based stock plan leads Maze Therapeutics (MAZE) exec to sell shares and log 20,000 RSUs - Stock Titan
Maze Therapeutics (MAZE) legal chief gets 11,000 shares - Stock Titan
Officer plans to sell up to $623K in Maze Therapeutics (MAZE) stock from vested RSUs - Stock Titan
Maze Therapeutics to Participate in Three Upcoming Investor Conferences - Yahoo Finance
MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences - Yahoo Finance
Maze Therapeutics CSBO Dandekar divests $206,823 of common stock - Investing.com India
Maze Therapeutics CSBO Dandekar divests $206,823 of common stock By Investing.com - Investing.com UK
Maze Therapeutics (MAZE) exec sells 7,500 shares under 10b5-1 plan - Stock Titan
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates - Eastern Progress
MAZE Q1 2026 Earnings: 19.14% EPS Beat Tempers Loss but Shares Slip 2.76%Performance Review - vinanet.vn
Maze Therapeutics (MAZE) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Maze (MAZE) Latest: Finishes 1.73% Higher at $29.43 for the Current Session; Price Context: the Session Ends Within the Reported Technical Boundaries under the Current SnapshotBreak of Structure - vinanet.vn
Maze (MAZE) Levels: Rises 1.73% to $29.43 in the Latest Reading; Current Setup: the Session Ends Within the Reported Technical Boundaries in the Latest SessionPullback Trade - vinanet.vn
Maze (MAZE) Trading: Ends Lower by 4.18% at $28.50 in the Latest Session; Price Context: the $27.07 to $29.93 Range Remains in FocusMESA MA - vinanet.vn
Maze (MAZE) Price: Climbs 0.72% to $29.34 at the Close; Market Levels: Support at $27.87 and Resistance at $30.81 Frame the RangeVolume Oscillator - vinanet.vn
Trv Gp Iv LLC Invests $133.50 Billion in Maze Therapeutics, Inc. $MAZE - MarketBeat
Trv Gp V LLC Buys Shares of 950,800 Maze Therapeutics, Inc. $MAZE - MarketBeat
Alphabet Inc. Acquires New Stake in Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics Confirms MZE829 Data Readout for Late 2026 or Early 2027 - Minichart
Maze Therapeutics Names Paula A. Johnson and Sophie Kornowski to Board of Directors - Kalkine Media
Maze Therapeutics (MAZE) awards director 36,000 stock options - Stock Titan
Maze Therapeutics (MAZE) awards director 36K stock options - Stock Titan
Maze Therapeutics (NASDAQ: MAZE) director shows no stock or derivative holdings - Stock Titan
Maze Therapeutics (MAZE) director begins reporting with zero shares disclosed - Stock Titan
Maze Therapeutics Director Paula A. Johnson Awarded 36,000 Stock Options - Kalkine Media
Maze Therapeutics (MAZE) Pulls Back 1.75% as Shares Consolidate Above Key SupportMomentum Factor - vinanet.vn
128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa
Maze Therapeutics president sells $445,620 in company stock - Investing.com
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock - MarketBeat
Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan - Stock Titan
Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64 - Moomoo
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):